IGC Pharma, Inc. (IGC)
AMEX·Healthcare·Biotechnology
$0.31
-2.09%
Mkt Cap $27.54M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q2 2026 Apr 3, 2026 | $246.50K | $300.00K | +21.70% | -$0.02 | -$0.01 | +50.00% | — | — |
| Q4 2025 Nov 14, 2025 | $383.00K | $191.00K | -50.13% | -$0.02 | -$0.02 | +0.00% | — | — |
| Q3 2025 Aug 14, 2025 | $383.00K | $328.00K | -14.36% | -$0.03 | -$0.02 | +33.33% | — | — |
| Q2 2025 Jun 27, 2025 | $305.00K | $330.00K | +8.20% | -$0.02 | -$0.01 | +50.00% | — | — |
| Q1 2025 Feb 14, 2025 | $295.00K | $257.00K | -12.88% | -$0.03 | -$0.02 | +33.33% | — | — |
| Q4 2024 Nov 12, 2024 | $300.00K | $412.00K | +37.33% | -$0.02 | -$0.02 | -23.08% | — | — |
| Q3 2024 Aug 8, 2024 | $272.00K | $272.00K | +0.00% | -$0.03 | -$0.03 | -15.92% | — | — |
| Q2 2024 Jun 24, 2024 | $190.00K | $295.00K | +55.26% | -$0.00 | -$0.04 | -900.00% | — | — |
| Q1 2024 Feb 14, 2024 | $190.00K | $204.00K | +7.37% | -$0.04 | -$0.09 | -125.00% | — | — |
| Q4 2023 Nov 9, 2023 | — | $291.00K | — | — | -$0.05 | — | — | — |
| Q3 2023 Jul 7, 2023 | — | $555.00K | — | — | -$0.08 | — | — | — |
| Q2 2023 Jun 30, 2023 | — | $166.00K | — | — | -$0.13 | — | — | — |
| Q1 2023 Feb 14, 2023 | — | $332.00K | — | — | -$0.04 | — | — | — |
| Q4 2022 Nov 1, 2022 | — | $202.00K | — | — | -$0.05 | — | — | — |
| Q3 2022 Aug 8, 2022 | — | $212.00K | — | — | -$0.05 | — | — | — |
| Q2 2022 Jun 22, 2022 | — | $122.00K | — | — | -$0.13 | — | — | — |
| Q1 2022 Feb 10, 2022 | — | $142.00K | — | — | -$0.05 | — | — | — |
| Q4 2021 Oct 29, 2021 | — | $56.00K | — | — | -$0.09 | — | — | — |
| Q3 2021 Aug 11, 2021 | — | $77.00K | — | — | -$0.04 | — | — | — |
| Q2 2021 Jun 14, 2021 | — | $81.00K | — | — | -$0.07 | — | — | — |